Crystal structure of the µ-opioid receptor bound to a morphinan antagonist.

Molecular signatures of G-protein-coupled receptors. Nature (2013) 5.19

Structure-function of the G protein-coupled receptor superfamily. Annu Rev Pharmacol Toxicol (2012) 3.83

Structure of the δ-opioid receptor bound to naltrindole. Nature (2012) 3.69

Structural basis for allosteric regulation of GPCRs by sodium ions. Science (2012) 3.40

Structure of the agonist-bound neurotensin receptor. Nature (2012) 3.23

Structure of the human smoothened receptor bound to an antitumour agent. Nature (2013) 3.08

Structure of the nociceptin/orphanin FQ receptor in complex with a peptide mimetic. Nature (2012) 2.96

Structure of the human glucagon class B G-protein-coupled receptor. Nature (2013) 2.86

High-resolution crystal structure of human protease-activated receptor 1. Nature (2012) 2.44

Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42

Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors. PLoS Biol (2015) 2.30

Micro-crystallography comes of age. Curr Opin Struct Biol (2012) 2.17

Fusion partner toolchest for the stabilization and crystallization of G protein-coupled receptors. Structure (2012) 2.08

Crystal structure of oligomeric β1-adrenergic G protein-coupled receptors in ligand-free basal state. Nat Struct Mol Biol (2013) 2.06

G protein-coupled receptor oligomerization revisited: functional and pharmacological perspectives. Pharmacol Rev (2014) 1.82

Structure-based discovery of opioid analgesics with reduced side effects. Nature (2016) 1.79

Structural insights into µ-opioid receptor activation. Nature (2015) 1.77

Structure-based drug screening for G-protein-coupled receptors. Trends Pharmacol Sci (2012) 1.72

Mu opioids and their receptors: evolution of a concept. Pharmacol Rev (2013) 1.66

Development of κ opioid receptor antagonists. J Med Chem (2013) 1.61

Membrane protein structure determination using crystallography and lipidic mesophases: recent advances and successes. Biochemistry (2012) 1.57

The GPCR Network: a large-scale collaboration to determine human GPCR structure and function. Nat Rev Drug Discov (2012) 1.50

A new era of GPCR structural and chemical biology. Nat Chem Biol (2012) 1.41

Allosteric sodium in class A GPCR signaling. Trends Biochem Sci (2014) 1.41

Identification of a μ-δ opioid receptor heteromer-biased agonist with antinociceptive activity. Proc Natl Acad Sci U S A (2013) 1.34

Structural basis for bifunctional peptide recognition at human δ-opioid receptor. Nat Struct Mol Biol (2015) 1.32

Opioid receptors: distinct roles in mood disorders. Trends Neurosci (2012) 1.31

κ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. Trends Neurosci (2012) 1.29

The structural basis of G-protein-coupled receptor signaling (Nobel Lecture). Angew Chem Int Ed Engl (2013) 1.25

Structural determinants of the supramolecular organization of G protein-coupled receptors in bilayers. J Am Chem Soc (2012) 1.20

The prevalence, maintenance, and relevance of G protein-coupled receptor oligomerization. Mol Pharmacol (2013) 1.14

Propagation of conformational changes during μ-opioid receptor activation. Nature (2015) 1.14

Modulation of opioid receptor ligand affinity and efficacy using active and inactive state receptor models. Chem Biol Drug Des (2012) 1.14

Harvesting and cryo-cooling crystals of membrane proteins grown in lipidic mesophases for structure determination by macromolecular crystallography. J Vis Exp (2012) 1.13

Ligand-directed signalling within the opioid receptor family. Br J Pharmacol (2012) 1.13

GPCRdb: an information system for G protein-coupled receptors. Nucleic Acids Res (2015) 1.12

Novel molecular targets of dezocine and their clinical implications. Anesthesiology (2014) 1.08

Optimising the combination of thermostabilising mutations in the neurotensin receptor for structure determination. Biochim Biophys Acta (2013) 1.07

Discovery of positive allosteric modulators and silent allosteric modulators of the μ-opioid receptor. Proc Natl Acad Sci U S A (2013) 1.06

Structural basis for Smoothened receptor modulation and chemoresistance to anticancer drugs. Nat Commun (2014) 1.05

Grand opening of structure-guided design for novel opioids. Trends Pharmacol Sci (2012) 1.04

Transactivation of the PAR1-PAR2 heterodimer by thrombin elicits β-arrestin-mediated endosomal signaling. J Biol Chem (2013) 1.03

Crystal structure of the human OX2 orexin receptor bound to the insomnia drug suvorexant. Nature (2014) 1.03

Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev (2016) 1.02

Assessing the relative stability of dimer interfaces in g protein-coupled receptors. PLoS Comput Biol (2012) 1.02

Structural determinants of arrestin functions. Prog Mol Biol Transl Sci (2013) 1.01

Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol (2014) 0.99

Biophysical fragment screening of the β1-adrenergic receptor: identification of high affinity arylpiperazine leads using structure-based drug design. J Med Chem (2013) 0.99

Stabilization of the μ-opioid receptor by truncated single transmembrane splice variants through a chaperone-like action. J Biol Chem (2013) 0.99

Insights into the molecular evolution of oxytocin receptor ligand binding. Biochem Soc Trans (2013) 0.99

Predicted structure of agonist-bound glucagon-like peptide 1 receptor, a class B G protein-coupled receptor. Proc Natl Acad Sci U S A (2012) 0.98

New insights for drug design from the X-ray crystallographic structures of G-protein-coupled receptors. Mol Pharmacol (2012) 0.98

15 years of genetic approaches in vivo for addiction research: Opioid receptor and peptide gene knockout in mouse models of drug abuse. Neuropharmacology (2013) 0.97

Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol (2014) 0.97

Cholesterol as a co-solvent and a ligand for membrane proteins. Protein Sci (2013) 0.97

Discovery of a novel selective kappa-opioid receptor agonist using crystal structure-based virtual screening. J Chem Inf Model (2013) 0.96

CrossTalk proposal: Weighing the evidence for Class A GPCR dimers, the evidence favours dimers. J Physiol (2014) 0.95

The role of a sodium ion binding site in the allosteric modulation of the A(2A) adenosine G protein-coupled receptor. Structure (2013) 0.95

Long-acting κ opioid antagonists nor-BNI, GNTI and JDTic: pharmacokinetics in mice and lipophilicity. BMC Pharmacol (2012) 0.95

Chemotype-selective modes of action of κ-opioid receptor agonists. J Biol Chem (2013) 0.95

Heteromerization of chemokine (C-X-C motif) receptor 4 with α1A/B-adrenergic receptors controls α1-adrenergic receptor function. Proc Natl Acad Sci U S A (2015) 0.94

Structure and function of serotonin G protein-coupled receptors. Pharmacol Ther (2015) 0.94

Increased agonist affinity at the μ-opioid receptor induced by prolonged agonist exposure. J Neurosci (2013) 0.94

Novel GPCR paradigms at the μ-opioid receptor. Br J Pharmacol (2014) 0.93

Glucose-neopentyl glycol (GNG) amphiphiles for membrane protein study. Chem Commun (Camb) (2013) 0.93

Structural biology: How opioid drugs bind to receptors. Nature (2012) 0.92

Cofactoring and dimerization of proteinase-activated receptors. Pharmacol Rev (2013) 0.92

Structural prerequisites for G-protein activation by the neurotensin receptor. Nat Commun (2015) 0.92

Allosteric coupling from G protein to the agonist-binding pocket in GPCRs. Nature (2016) 0.92

Opioid receptor desensitization: mechanisms and its link to tolerance. Front Pharmacol (2014) 0.91

Delta opioid receptors in brain function and diseases. Pharmacol Ther (2013) 0.91

Mechanistic insights into the allosteric modulation of opioid receptors by sodium ions. Biochemistry (2014) 0.91

Segregation of family A G protein-coupled receptor protomers in the plasma membrane. Mol Pharmacol (2013) 0.91

G protein-coupled receptors--recent advances. Acta Biochim Pol (2012) 0.90

Synthesis, modeling, and pharmacological evaluation of UMB 425, a mixed μ agonist/δ antagonist opioid analgesic with reduced tolerance liabilities. ACS Chem Neurosci (2013) 0.90

From atomic structures to neuronal functions of g protein-coupled receptors. Annu Rev Neurosci (2013) 0.90

Positive allosteric modulators of the μ-opioid receptor: a novel approach for future pain medications. Br J Pharmacol (2014) 0.90

Probes for narcotic receptor mediated phenomena. 46. N-substituted-2,3,4,9,10,10a-hexahydro-1H-1,4a-(epiminoethano)phenanthren-6- and 8-ols - carbocyclic relatives of f-oxide-bridged phenylmorphans. Eur J Med Chem (2012) 0.90

Structural basis of G protein-coupled receptor-Gi protein interaction: formation of the cannabinoid CB2 receptor-Gi protein complex. J Biol Chem (2014) 0.89

The recombinant expression systems for structure determination of eukaryotic membrane proteins. Protein Cell (2014) 0.89

Probing insect odorant receptors with their cognate ligands: insights into structural features. Biochem Biophys Res Commun (2013) 0.89

GPCR activation: protonation and membrane potential. Protein Cell (2013) 0.89

Similarity between class A and class B G-protein-coupled receptors exemplified through calcitonin gene-related peptide receptor modelling and mutagenesis studies. J R Soc Interface (2012) 0.88

Opiate pharmacology and relief of pain. J Clin Oncol (2014) 0.88

Molecular basis for dramatic changes in cannabinoid CB1 G protein-coupled receptor activation upon single and double point mutations. Protein Sci (2013) 0.88

A novel bivalent HIV-1 entry inhibitor reveals fundamental differences in CCR5-μ-opioid receptor interactions between human astroglia and microglia. AIDS (2013) 0.88

A computationally designed water-soluble variant of a G-protein-coupled receptor: the human mu opioid receptor. PLoS One (2013) 0.88

A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design. Br J Pharmacol (2013) 0.88

Transmembrane peptides as unique tools to demonstrate the in vivo action of a cross-class GPCR heterocomplex. FASEB J (2014) 0.87

Compound activity prediction using models of binding pockets or ligand properties in 3D. Curr Top Med Chem (2012) 0.87

Why GPCRs behave differently in cubic and lamellar lipidic mesophases. J Am Chem Soc (2012) 0.87

Orvinols with mixed kappa/mu opioid receptor agonist activity. J Med Chem (2013) 0.87

Basic Pharmacological and Structural Evidence for Class A G-Protein-Coupled Receptor Heteromerization. Front Pharmacol (2016) 0.87

Mitragynine/Corynantheidine Pseudoindoxyls As Opioid Analgesics with Mu Agonism and Delta Antagonism, Which Do Not Recruit β-Arrestin-2. J Med Chem (2016) 0.87

Molecular properties of muscarinic acetylcholine receptors. Proc Jpn Acad Ser B Phys Biol Sci (2013) 0.87

Preferred supramolecular organization and dimer interfaces of opioid receptors from simulated self-association. PLoS Comput Biol (2015) 0.86

A functional selectivity mechanism at the serotonin-2A GPCR involves ligand-dependent conformations of intracellular loop 2. J Am Chem Soc (2014) 0.86

Ligands raise the constraint that limits constitutive activation in G protein-coupled opioid receptors. J Biol Chem (2013) 0.86

Molecular details of the activation of the μ opioid receptor. J Phys Chem B (2013) 0.86

Fluorescent approaches for understanding interactions of ligands with G protein coupled receptors. Biochim Biophys Acta (2013) 0.86

Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01

Phaser crystallographic software. J Appl Crystallogr (2007) 108.34

MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr (2009) 53.36

Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92

GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74

Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science (2010) 10.30

Endogenous opioid peptides: multiple agonists and receptors. Nature (1977) 8.21

Crystal structure of the ligand-free G-protein-coupled receptor opsin. Nature (2008) 7.20

Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature (1996) 7.15

Crystallizing membrane proteins using lipidic mesophases. Nat Protoc (2009) 6.36

A robust bulk-solvent correction and anisotropic scaling procedure. Acta Crystallogr D Biol Crystallogr (2005) 4.82

G-protein-coupled receptor heterodimerization modulates receptor function. Nature (1999) 4.73

A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 3.87

Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83

Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature (2012) 3.83

A peptide derived from a beta2-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation. J Biol Chem (1996) 3.77

Oligomerization of mu- and delta-opioid receptors. Generation of novel functional properties. J Biol Chem (2000) 3.22

Acute heroin overdose. Ann Intern Med (1999) 2.64

Conformational cross-talk between alpha2A-adrenergic and mu-opioid receptors controls cell signaling. Nat Chem Biol (2008) 2.51

Emerging paradigms of β-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci (2011) 2.51

Facilitation of μ-opioid receptor activity by preventing δ-opioid receptor-mediated codegradation. Neuron (2011) 2.42

Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell (2002) 2.40

Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer. EMBO J (2009) 1.86

Design of peptidomimetic delta opioid receptor antagonists using the message-address concept. J Med Chem (1990) 1.68

Morphine-like opiates selectively antagonize receptor-arrestin interactions. J Biol Chem (2010) 1.45

Selectivity of mu-opioid receptor determined by interfacial residues near third extracellular loop. Eur J Pharmacol (2000) 1.32

Functional role of a conserved motif in TM6 of the rat mu opioid receptor: constitutively active and inactive receptors result from substitutions of Thr6.34(279) with Lys and Asp. Biochemistry (2001) 1.29

An opiate cocktail that reduces morphine tolerance and dependence. Curr Biol (2005) 1.27

G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27

Ba 679 BR, a novel long-acting anticholinergic bronchodilator. Life Sci (1993) 1.22

Determination of the amino acid residue involved in [3H]beta-funaltrexamine covalent binding in the cloned rat mu-opioid receptor. J Biol Chem (1996) 1.20

Making structural sense of dimerization interfaces of delta opioid receptor homodimers. Biochemistry (2011) 1.13

Key residues defining the mu-opioid receptor binding pocket: a site-directed mutagenesis study. J Neurochem (1997) 1.10

Update 1 of: computational modeling approaches to structure-function analysis of G protein-coupled receptors. Chem Rev (2011) 1.08

Differential response to morphine of the oligomeric state of μ-opioid in the presence of δ-opioid receptors. Biochemistry (2011) 1.03

A cyclic peptide mimicking the third intracellular loop of the V2 vasopressin receptor inhibits signaling through its interaction with receptor dimer and G protein. J Biol Chem (2004) 1.00

G-protein antisense oligodeoxyribonucleotides and mu-opioid supraspinal antinociception. Eur J Pharmacol (1994) 0.99

DAMGO recognizes four residues in the third extracellular loop to discriminate between mu- and kappa-opioid receptors. Eur J Pharmacol (1998) 0.97

[(3)H]Alvimopan binding to the micro opioid receptor: comparative binding kinetics of opioid antagonists. Eur J Pharmacol (2005) 0.96

[3H]-etorphine and [3H]-diprenorphine receptor binding in vitro and in vivo: differential effect of Na+ and guanylyl imidodiphosphate. Brain Res (1982) 0.90

Etorphine and diprenorphine as immobilizing and reversing agents in captive and free-ranging mammals. J Am Vet Med Assoc (1974) 0.88

High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science (2007) 20.32

Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature (2007) 14.06

Crystal structure of the β2 adrenergic receptor-Gs protein complex. Nature (2011) 13.92

GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74

Structure of a nanobody-stabilized active state of the β(2) adrenoceptor. Nature (2011) 9.61

Deconstructing the cadherin-catenin-actin complex. Cell (2005) 8.39

The structure and function of G-protein-coupled receptors. Nature (2009) 8.08

Alpha-catenin is a molecular switch that binds E-cadherin-beta-catenin and regulates actin-filament assembly. Cell (2005) 7.62

A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci U S A (2007) 6.04

Structure and function of an irreversible agonist-β(2) adrenoceptor complex. Nature (2011) 5.35

betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science (2002) 4.47

The dynamic process of β(2)-adrenergic receptor activation. Cell (2013) 4.09

Structure and dynamics of the M3 muscarinic acetylcholine receptor. Nature (2012) 3.83

Structure of the human M2 muscarinic acetylcholine receptor bound to an antagonist. Nature (2012) 3.83

Structure of the δ-opioid receptor bound to naltrindole. Nature (2012) 3.69

Beta-catenin directly displaces Groucho/TLE repressors from Tcf/Lef in Wnt-mediated transcription activation. Nat Struct Mol Biol (2005) 3.41

Conformational biosensors reveal GPCR signalling from endosomes. Nature (2013) 3.29

Ligand-specific regulation of the extracellular surface of a G-protein-coupled receptor. Nature (2010) 3.19

Linkage of beta1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/calmodulin kinase II. J Clin Invest (2003) 3.15

Structure and mechanism of cadherins and catenins in cell-cell contacts. Annu Rev Cell Dev Biol (2007) 2.86

The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc Natl Acad Sci U S A (2009) 2.86

Structural basis for distinct ligand-binding and targeting properties of the receptors DC-SIGN and DC-SIGNR. Nat Struct Mol Biol (2004) 2.83

E-cadherin is under constitutive actomyosin-generated tension that is increased at cell-cell contacts upon externally applied stretch. Proc Natl Acad Sci U S A (2012) 2.82

An epithelial tissue in Dictyostelium challenges the traditional origin of metazoan multicellularity. Bioessays (2012) 2.81

Maltose-neopentyl glycol (MNG) amphiphiles for solubilization, stabilization and crystallization of membrane proteins. Nat Methods (2010) 2.77

Sequential binding of agonists to the beta2 adrenoceptor. Kinetic evidence for intermediate conformational states. J Biol Chem (2003) 2.68

Probing the beta2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem (2005) 2.64

Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem (2007) 2.59

Conformational changes of p97 during nucleotide hydrolysis determined by small-angle X-Ray scattering. Structure (2005) 2.53

Activation and allosteric modulation of a muscarinic acetylcholine receptor. Nature (2013) 2.49

Structure-based discovery of beta2-adrenergic receptor ligands. Proc Natl Acad Sci U S A (2009) 2.48

High-resolution crystal structure of human protease-activated receptor 1. Nature (2012) 2.44

Conformational changes in the G protein Gs induced by the β2 adrenergic receptor. Nature (2011) 2.43

Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle. Nat Struct Biol (2002) 2.38

Structure and biochemistry of cadherins and catenins. Cold Spring Harb Perspect Biol (2009) 2.37

Improved structures of full-length p97, an AAA ATPase: implications for mechanisms of nucleotide-dependent conformational change. Structure (2008) 2.36

Munc18a controls SNARE assembly through its interaction with the syntaxin N-peptide. EMBO J (2008) 2.33

Biochemical and structural definition of the l-afadin- and actin-binding sites of alpha-catenin. J Biol Chem (2002) 2.31

Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase. Mol Cell (2006) 2.28

The β-catenin destruction complex. Cold Spring Harb Perspect Biol (2013) 2.22

Structure of active β-arrestin-1 bound to a G-protein-coupled receptor phosphopeptide. Nature (2013) 2.14

Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol Cell (2004) 2.13

Energy landscapes as a tool to integrate GPCR structure, dynamics, and function. Physiology (Bethesda) (2010) 2.05

Thermodynamics of beta-catenin-ligand interactions: the roles of the N- and C-terminal tails in modulating binding affinity. J Biol Chem (2005) 2.04

Structural flexibility of the G alpha s alpha-helical domain in the beta2-adrenoceptor Gs complex. Proc Natl Acad Sci U S A (2011) 2.03

Counting low-copy number proteins in a single cell. Science (2007) 2.01

Structures of two intermediate filament-binding fragments of desmoplakin reveal a unique repeat motif structure. Nat Struct Biol (2002) 1.97

A molecular dissection of the glycoprotein hormone receptors. Trends Biochem Sci (2004) 1.89

ICAT inhibits beta-catenin binding to Tcf/Lef-family transcription factors and the general coactivator p300 using independent structural modules. Mol Cell (2002) 1.88

Antithetic regulation by beta-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway beta-agonist paradox. J Clin Invest (2003) 1.87

Direct inhibition of GSK3beta by the phosphorylated cytoplasmic domain of LRP6 in Wnt/beta-catenin signaling. PLoS One (2008) 1.86

Ligand-regulated oligomerization of beta(2)-adrenoceptors in a model lipid bilayer. EMBO J (2009) 1.86

T cell receptor signaling is limited by docking geometry to peptide-major histocompatibility complex. Immunity (2011) 1.86

Ligand-specific interactions modulate kinetic, energetic, and mechanical properties of the human β2 adrenergic receptor. Structure (2012) 1.85

AlphaE-catenin regulates actin dynamics independently of cadherin-mediated cell-cell adhesion. J Cell Biol (2010) 1.81

Myocyte adrenoceptor signaling pathways. Science (2003) 1.81

Structure-based discovery of opioid analgesics with reduced side effects. Nature (2016) 1.79